John Scarlett, Geron Corporation CEO
Data to dollars: Geron sells stock to raise over $200M after PhIII readout on MDS drug
Following a Phase III readout last week on its blood cancer drug, Geron has raised about $213 million via a public offering.
The money will …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
